Wegovy semaglutide tablets.
Michael Siluk | Common Photographs Group | Getty Photographs
Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy weight problems drug merchandise that goals to make sure cash-paying sufferers see decrease, “predictable” month-to-month costs.
Eligible sufferers can select between three-, six- or 12-month subscriptions for the Wegovy injection or the 2 highest doses of the newly launched tablet beneath the identical model title. Longer plans supply decrease month-to-month pricing, and the corporate expects folks to avoid wasting as much as $1,200 a yr on the injection and as a lot as $600 a yr on the tablet, relative to paying for his or her particular person dose every month, in response to a Novo launch.
Sufferers can anticipate to pay flat month-to-month costs, even when they transfer to totally different doses, the corporate stated. The subscription program might be accessible beginning Tuesday on a number of of Novo’s telehealth companions, together with Ro, WeightWatchers and LifeMD. Sesame, Hims & Hers and extra are anticipated to be added quickly.
The primary-of-its-kind providing is “a chance to assist sufferers not solely begin however keep on remedy and assist them handle the ups and downs of among the pricing concerns,” regardless if they’re beginning therapy or are at the moment taking the drug, stated Ed Cinca, Novo’s head of promoting and affected person options.
Incapability to remain on GLP-1s is a longstanding situation because of components similar to problem accessing the medication and gastrointestinal unwanted effects, with one 2025 examine estimating that round 65% of sufferers with weight problems cease therapy inside a yr.
Wegovy subscription costs and estimated financial savings
Injection subscription plans (0.25, 0.5, 1.7 and a pair of.4 milligram doses)
- 3-month: $329 per 30 days, financial savings of $240 per yr
- 6-month: $299 per 30 days, financial savings of $600 per yr
- 12-month: $249 per 30 days, financial savings of $1,200 per yr
Capsule subscription plans (9 and 25 milligram doses)
- 3-month: $289 per 30 days, financial savings of $120 per yr
- 6-month: $269 per 30 days, financial savings of $360 per yr
- 12-month: $249 per 30 days, financial savings of $600 per yr
The brand new program additionally comes as Novo’s tablet, which has seen explosive uptake since its U.S. launch in January, is about to face contemporary competitors from an upcoming oral GLP-1 from chief rival Eli Lilly later this yr. Lilly is at the moment the dominant participant within the branded GLP-1 market within the U.S., with an estimated 60% share, whereas Novo has about 39%.
The Wegovy tablet has largely been reaching individuals who did not beforehand take GLP-1 injections, making it essential for Novo to seize as many new sufferers as it may well earlier than a competitor arrives.
As Novo Nordisk’s subscription plans launch, cash-paying sufferers can nonetheless pay $149 per 30 days for the decrease doses of the tablet, that are 1.5 and 4 milligrams. However beginning in September, the 4-milligram dose will price $199 per 30 days. In the meantime, the lately authorised 7.2-milligram dose of Wegovy might be added to the subscription program at a later date.
Cinca emphasised that sufferers can decide out of the subscription whereas it is lively in the event that they not want to enroll.
“We need to assist sufferers determine a path that may assist them really feel snug about treating [obesity] in the long run,” he added.
Cinca stated Novo is just not but providing this system on its NovoCare direct-to-consumer pharmacy, however added that there is “a chance to guage how this goes after which construct it out” by that platform over time.
